Cancer risk in hyperprolactinemia patients: a population-based cohort study
Authors:
- Katarina BerinderKBKatarina Berinder
- Olof AkreOAOlof Akre
- Fredrik GranathFGFredrik Granath
- Anna-Lena HultingAHAnna-Lena Hulting
- 1 August 2011
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 165 (2) , 209-215
Abstract
Experimental evidence indicates that prolactin might play a role in tumorigenesis of several human cancers, but data on cancer risk in hyperprolactinemia patients are sparse. The aim of this study was to investigate cancer risk in hyperprolactinemia patients. Design A population-based matched cohort study in Sweden. The hyperprolactinemia cohort consisted of patients hospitalized for hyperprolactinemia from 1987 to 1995 identified in the National Patient Register (n=585) and a hospital cohort of prolactinoma patients at Karolinska University Hospital (n=384). For each patient, ten matched individuals were identified via the Register of Population. Cancer occurrence was ascertained via the Swedish Cancer Registry. Hazard ratios (HRs) were estimated by Cox proportional hazards regression. Seventy-three malignant tumors were identified in the hyperprolactinemia patients and 660 tumors in the comparison group (HR 1.31; 95% confidence interval (CI): 1.02-1.68), mainly attributed to an increased risk of upper gastrointestinal cancer in both males and females (HR 3.69; 95% CI: 1.70-8.03) and hematopoietic cancer in females (HR 3.51; 95% CI: 1.06-11.6). Twelve breast cancers occurred in the female patients, corresponding to an HR of 1.09 (95% CI: 0.60-1.99). Prostate cancer risk in hyperprolactinemia men was reduced (HR 0.40; 95% CI: 0.16-0.99). An increased overall cancer risk was found in hyperprolactinemia patients, but no increased risk of breast cancer in women and a reduced risk of prostate cancer in men. These findings warrant further investigations and to be confirmed in larger studies but may indicate the importance of an active treatment strategy and follow-up of hyperprolactinemia patients.Keywords
This publication has 42 references indexed in Scilit:
- The risk for breast cancer is not evidently increased in women with hyperprolactinemiaPituitary, 2009
- Biological Significance of Prolactin in Gynecologic CancersCancer Research, 2009
- The Swedish personal identity number: possibilities and pitfalls in healthcare and medical researchEuropean Journal of Epidemiology, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Advances in Male ContraceptionEndocrine Reviews, 2008
- Prolactin stimulates prostate cell proliferation by increasing endoplasmic reticulum content due to SERCA 2b over-expressionBiochemical Journal, 2006
- Cancer risk among users of neuroleptic medication: a population-based cohort studyBritish Journal of Cancer, 2006
- Possible role for protein kinase B in the anti-apoptotic effect of prolactin in rat Nb2 lymphoma cellsJournal of Endocrinology, 2000
- Prolactin as a local growth promoter in patients with locally advanced tongue cancer: GCRI experienceHead & Neck, 2000
- Increased incidence of neoplasia in patients with pituitary adenomasClinical Endocrinology, 1998